Von Willebrand Disease: An Introduction

Prev
 1 / 22 
Next
Prev
 1 / 22 
Next

Learning objectives

After completing this quiz, the learner should be able to:

  • explain how von Willebrand factor connects vascular injury, platelet adhesion, blood flow, and coagulation.
  • distinguish the typical bleeding patterns of von Willebrand disease and hemophilia by relating phenotype to mechanism.
  • interpret how quantitative and qualitative defects in von Willebrand factor produce different laboratory patterns.
  • recognize why von Willebrand disease represents a spectrum rather than a single uniform disorder.
  • evaluate suspected von Willebrand disease by integrating bleeding phenotype, family context, and laboratory findings.
  • apply mechanism-based reasoning when selecting treatment for a particular patient and hemostatic challenge.
  • identify why hemostatic challenges often reveal von Willebrand disease more clearly than everyday symptoms.
  • integrate biological variation, assay results, and clinical context into diagnostic reasoning.

Which statement best explains why von Willebrand factor is described as a link between primary and secondary hemostasis?

a
It supports platelet adhesion and protects circulating factor VIII from premature clearance.
Von Willebrand factor supports platelet tethering and adhesion at sites of vascular injury, placing it within primary hemostasis. It also binds and stabilizes factor VIII, preserving an essential component of secondary hemostasis. These functions explain why VWD usually causes mucocutaneous bleeding but may also produce deep tissue bleeding when factor VIII becomes markedly reduced.
b
It activates factor VIII and directly converts fibrinogen into fibrin at sites of vascular injury.
Von Willebrand factor does not convert fibrinogen into fibrin. Thrombin performs that function. VWF stabilizes factor VIII but does not directly activate it in the manner described.
c
It limits fibrinolysis and promotes platelet production during acute bleeding.
Von Willebrand factor is not a principal inhibitor of fibrinolysis and does not regulate platelet production in the bone marrow.
d
It binds platelets only after thrombin has generated a stable fibrin network.
Von Willebrand factor acts early in hemostasis by helping platelets tether to the injured vessel wall. Its role is not limited to events occurring after fibrin formation.

A patient with severe type 3 VWD develops recurrent hemarthroses and intramuscular bleeding.

Which mechanism best explains this phenotype?

a
Enhanced platelet binding causes platelet consumption and reduced multimer size
Enhanced platelet binding is characteristic of type 2B VWD. It may cause thrombocytopenia and loss of high-molecular-weight multimers but does not explain the profound factor VIII reduction seen in type 3 VWD.
b
Defective collagen binding prevents effective platelet adhesion to the subendothelium.
Defective collagen binding can occur in selected qualitative variants, but it does not account for the near absence of VWF and markedly reduced factor VIII.
c
Near absence of VWF permits rapid factor VIII clearance and impairs secondary hemostasis.
Type 3 VWD is characterized by near-complete or complete absence of VWF. Without VWF to protect factor VIII, circulating factor VIII may fall to very low levels. This creates a secondary hemostatic defect that can resemble severe hemophilia, including hemarthroses and deep tissue bleeding.
d
Increased local fibrinolysis prevents stable clot formation in joints and muscles.
Fibrinolysis contributes importantly to bleeding at mucosal surfaces, but it is not the primary mechanism responsible for deep tissue and joint bleeding in type 3 VWD.

What is the most clinically useful purpose of classifying VWD into types and subtypes?

a
To estimate bleeding severity from the subtype designation before reviewing the history.
Subtype does not predict bleeding severity with precision. Patients with the same subtype may have substantially different bleeding phenotypes.
b
To localize the dominant biological defect and guide testing and treatment.
VWD classification helps identify whether the dominant problem involves VWF quantity, multimer distribution, platelet binding, collagen binding, factor VIII binding, or clearance. This biological localization helps clinicians interpret laboratory patterns, assess inheritance, anticipate treatment response, and select therapy.
c
To determine which patients will require lifelong prophylaxis.
The need for prophylaxis depends on bleeding history, clinical severity, treatment response, and recurrent hemostatic challenges. It cannot be determined from subtype alone.
d
To distinguish inherited VWD from every acquired bleeding disorder.
The inherited classification system does not by itself exclude acquired von Willebrand syndrome or other acquired bleeding disorders.

A 25-year-old woman with lifelong heavy menstrual bleeding has a VWF antigen level of 37 IU/dL when well. During pregnancy, her VWF antigen rises to 96 IU/dL.

Which interpretation is most appropriate?

a
The difference is most consistent with a preanalytical problem affecting the first sample.
Preanalytical error is possible, but the rise during pregnancy is biologically plausible and expected. Physiological variation provides a more coherent explanation.
b
The pregnancy result makes an inherited abnormality of VWF biology less likely.
Pregnancy commonly raises VWF levels. A normal result during pregnancy therefore does not substantially reduce the possibility of inherited VWD or low VWF.
c
The increase suggests that her bleeding is unrelated to von Willebrand factor.
A pregnancy-associated increase does not establish that the bleeding has another cause. It demonstrates that VWF levels can change substantially over time.
d
VWF levels are dynamic and must be interpreted in physiological context.
VWF levels vary with pregnancy, age, stress, inflammation, exercise, acute bleeding, and other physiological conditions. A normal or elevated result during pregnancy does not eliminate an underlying tendency toward low VWF at baseline. Diagnosis requires interpretation of the assay in the context in which the sample was obtained.

A 22-year-old woman has lifelong epistaxis and easy bruising. Laboratory testing shows:

  • Platelet count: 86 × 10⁹/L
  • VWF antigen: 54 IU/dL
  • Platelet-dependent VWF activity: 20 IU/dL
  • Factor VIII activity: 63 IU/dL
  • High-molecular-weight multimers: Reduced
  • Low-dose ristocetin-induced platelet aggregation: Increased

Which mechanism best explains this pattern?

a
Increased VWF affinity for platelet GPIbα caused by an A1-domain variant
This pattern is characteristic of type 2B VWD. Increased affinity of VWF for platelet GPIbα causes exaggerated platelet binding, variable thrombocytopenia, and loss of high-molecular-weight multimers. The disproportionately reduced platelet-dependent activity and increased low-dose ristocetin response help localize the defect to enhanced platelet binding. Platelet-type VWD can produce a nearly identical phenotype through a gain-of-function defect in platelet GPIbα rather than VWF. Specialized platelet-mixing studies or genetic testing may be required to distinguish the two.
b
Defective VWF binding to factor VIII caused by a D′/D3-domain variant
Defective factor VIII binding causes type 2N VWD. Type 2N usually presents with disproportionately low factor VIII, preserved platelet-dependent VWF activity, and normal multimers.
c
Near-complete failure of VWF synthesis caused by biallelic null variants
Near-complete absence of VWF would produce type 3 VWD, with very low or undetectable VWF antigen and activity rather than the moderate antigen level shown here.
d
Reduced VWF production with proportionate preservation of platelet-binding function
A partial quantitative deficiency usually produces proportionate reductions in VWF antigen and activity. It would not explain increased low-dose ristocetin-induced platelet aggregation, thrombocytopenia, or selective loss of large multimers.

A 30-year-old woman has major postpartum hemorrhage. Laboratory testing performed when she is not pregnant shows:

  • VWF antigen: 84 IU/dL
  • Platelet-dependent VWF activity: 79 IU/dL
  • Factor VIII activity: 18 IU/dL
  • VWF multimers: Normal

Her brother has been treated for presumed mild hemophilia A.

Which diagnosis best explains the findings?

a
Type 1 VWD with proportionate reduction of VWF and factor VIII
Type 1 VWD usually causes proportionate reduction of VWF antigen and activity. The preserved VWF measurements and markedly low factor VIII argue against type 1 VWD.
b
Type 2M VWD with impaired platelet binding and preserved multimers
Type 2M VWD produces disproportionately low platelet-dependent activity relative to antigen. Platelet-dependent activity is preserved in this patient.
c
Type 2N VWD with defective binding and stabilization of factor VIII
Type 2N VWD results from defective binding of VWF to factor VIII, usually involving the D′/D3 region. VWF antigen and platelet-dependent activity may be preserved, while factor VIII is disproportionately reduced. Because type 2N is generally inherited in an autosomal recessive pattern, affected women may be identified, unlike the usual X-linked inheritance pattern of hemophilia A. A symptomatic hemophilia A carrier with skewed X-chromosome inactivation remains an important alternative diagnosis. A VWF–factor VIII binding assay and, when appropriate, genetic testing can distinguish type 2N VWD from hemophilia A carriership.
d
Type 3 VWD with near-complete absence of circulating VWF
Type 3 VWD would produce very low or undetectable VWF antigen and activity, often with absent multimers. That pattern is not present here.

A patient has recurrent heavy menstrual bleeding and VWF antigen levels ranging from 38 to 47 IU/dL on repeated baseline testing. Her sister has similar symptoms, while her mother has VWF antigen levels in the same range but no clinically important bleeding.

Which conclusion best reflects the biology of VWD?

a
A VWF antigen below 50 IU/dL defines the same disorder in every patient.
A mildly reduced VWF antigen does not have identical meaning in every patient. Phenotype, physiological context, family history, and repeat testing all matter.
b
Bleeding severity is determined primarily by the lowest recorded VWF antigen.
Bleeding severity does not correlate perfectly with the lowest antigen result. VWF function, comorbid conditions, hemostatic exposure, and additional modifiers also influence phenotype.
c
Mildly reduced VWF may lie on a spectrum from biological variation to clinically important disease.
VWF levels and bleeding symptoms both exist on a continuum. A mildly reduced VWF antigen may represent normal biological variation in one person, contribute to bleeding risk in another, or form part of a clinically meaningful VWD phenotype when supported by the bleeding history and broader laboratory pattern. The same numerical result can therefore have different clinical significance in different patients.
d
Normal bleeding in one relative makes an inherited contribution unlikely in the family.
Variable penetrance and differences in hemostatic challenges can produce different bleeding histories among relatives with similar VWF levels.

A woman has recurrent heavy menstrual bleeding, iron deficiency, and prolonged bleeding after two dental extractions. Her mother and sister also report heavy menstrual bleeding, although neither has been evaluated. VWF antigen and platelet-dependent activity are mildly and proportionately reduced on repeated baseline testing.

Which feature most strongly supports a clinically meaningful inherited bleeding tendency?

a
Iron deficiency occurring in a menstruating patient
Iron deficiency is an important consequence of heavy menstrual bleeding but is not specific for an inherited bleeding disorder.
b
Recurrent excessive bleeding during distinct hemostatic challenges
Repeated excessive bleeding during menstruation and dental extraction demonstrates a consistent phenotype across distinct hemostatic challenges. When this history is accompanied by reproducibly reduced VWF measurements and potentially affected relatives, the evidence becomes more coherent and clinically meaningful.
c
A family history limited to common mucosal symptoms
A family history of common mucosal symptoms may be supportive, but such symptoms can be normalized or nonspecific. The patient’s repeated challenge-related bleeding provides stronger evidence.
d
Proportionate reduction of VWF antigen and activity without a procedural history
A proportionate reduction may support a quantitative defect, but without a meaningful bleeding history or hemostatic challenge, its clinical significance remains uncertain.

Which factor best explains why the diagnosis of VWD is frequently delayed for many years?

a
Bleeding episodes may be intermittent, normalized, and attributed to unrelated causes.
VWD often becomes visible during menstruation, childbirth, surgery, dental work, or injury. These events may be separated by years and interpreted independently. Heavy menstrual bleeding may be normalized, epistaxis may be dismissed, and postoperative bleeding may be attributed to surgical factors. Diagnosis is delayed when clinicians and patients do not recognize these events as parts of one pattern.
b
VWF testing becomes reliable only after a major hemorrhagic event.
VWF testing may be informative in patients with mild or moderate bleeding. A major hemorrhage is not required before evaluation.
c
Most patients become symptomatic only after VWF levels decline with age.
VWF levels often rise rather than decline with age. Delayed diagnosis is more commonly caused by incomplete recognition of the bleeding pattern.
d
Clinical evaluation is usually deferred until a pathogenic variant is identified.
Most patients can be evaluated and diagnosed without first identifying a pathogenic variant.

A patient with VWD is preparing for surgery. Which approach best reflects mechanism-based treatment planning?

a
Use a standard replacement regimen based primarily on the diagnostic label.
Different biological defects require different approaches. Some patients respond well to desmopressin, while others require VWF replacement or additional therapies.
b
Select therapy according to the most recent VWF antigen level and procedural category.
A recent VWF antigen value and procedural category provide useful information but do not capture functional defects, prior treatment response, or the expected duration of bleeding risk.
c
Integrate subtype, prior bleeding, procedural risk, treatment response, and duration of risk.
Treatment should match the patient, the mechanism, and the hemostatic challenge. Planning requires consideration of VWD subtype, previous bleeding, expected procedural risk, response and durability after desmopressin, relevant comorbidities, and the duration for which hemostatic support will be needed.
d
Prioritize systemic therapy because local measures add little once VWF levels are corrected.
Local hemostatic measures may be essential during dental and surgical procedures and often complement systemic therapy.

Sort each item according to its primary role in VWD reasoning.

Normal VWF antigen during pregnancy
Proportionate reduction in VWF antigen and platelet-dependent activity
VWF antigen of 43 IU/dL
Proportionately low antigen and activity in a person with blood group O
Disproportionately reduced platelet-dependent activity
A historical VWD diagnosis with normal levels later in life
Rapid decline after an initial desmopressin response
Loss of high-molecular-weight multimers
Near-undetectable VWF antigen and activity
Absence of prior surgery, childbirth, or dental extraction
Recurrent postoperative bleeding
Preserved VWF measurements with disproportionately low factor VIII
Increased low-dose ristocetin-induced platelet aggregation
Heavy menstrual bleeding reported across several generations
Supports a quantitative VWF defect
Supports a qualitative VWF defect
Requires clinical context before interpretation

Match each subtype or physiological state with its most characteristic clue.

Type 1C VWD
Type 2A VWD
Type 1 VWD
Reduced activity with loss of large multimers
Rapid decline after an initial desmopressin response
Proportionate reduction in antigen and activity
Correct! Sorry, Incorrect.

Match each subtype or physiological state with its most characteristic clue.

Type 2M VWD
Type 2B VWD
Reduced activity with preserved multimers
Reduced activity with preserved multimers
Disproportionately low factor VIII
Enhanced platelet binding with possible thrombocytopenia
Correct! Sorry, Incorrect.

Key takeaways

  • VWF connects platelet adhesion with factor VIII biology.
  • VWD is a family of quantitative and qualitative disorders.
  • Subtype classification localizes biology more reliably than it predicts bleeding severity.
  • An activity-to-antigen ratio below approximately 0.7 suggests a qualitative defect.
  • VWF may rise with pregnancy, inflammation, stress, and age.
  • Diagnosis is strongest when bleeding phenotype, laboratory pattern, and mechanism align.

Closing Note

Von Willebrand disease is not defined adequately by a low laboratory value, a subtype label, or a list of bleeding symptoms. It is a disorder of dynamic VWF biology whose clinical expression depends on molecular function, physiological state, hemostatic challenge, and the individual patient. Good clinical reasoning begins by identifying the pattern, localizing the likely defect, and asking whether that mechanism explains the bleeding. The same reasoning guides treatment. The goal is not simply to raise a number or assign a category. It is to understand why this patient bleeds, in this setting, at this moment, and to choose an intervention that addresses that biological problem.

Prev
 1 / 22 
Next